OMH Osmetech

Osmetech Molecular Diagnostics announced today the appointment of John Bellano as Senior Vice President Commercial Operations. Mr. Bellano was recently Vice President Sales and a member of the executive team of Third Wave Technologies Inc, a leading molecular diagnostics company, until its acquisition by Hologic, Inc. in 2008. Following the acquisition, Mr. Bellano continued to lead the Third Wave sales teams as an integral component of Hologic’s sales and marketing organization.

“We are very pleased to welcome John to the Osmetech team and are looking forward to leveraging his extensive experience and prior success in building effective sales and marketing teams and developing new opportunities as we look to rapidly grow Osmetech’s market penetration,” stated Jon Faiz Kayyem, PhD, Chief Executive Officer of Osmetech.

In joining Osmetech, John Bellano commented, “I am very excited to be joining Osmetech’s executive team at a time when the company is growing its direct sales and marketing team and is expanding the menu for its award-winning eSensor® XT-8 molecular diagnostics platform.”

Osmetech Molecular Diagnostics is a wholly owned subsidiary of London Stock Exchange AIM listed, Osmetech plc (LSE:OMH). The business is focused on providing simple-to-perform, cost-effective and high-value molecular diagnostic tests that enable a broad range of hospitals and laboratories to offer molecular diagnostic services for improved patient care.

Osmetech (LSE:OMH)
Historical Stock Chart
From Dec 2024 to Jan 2025

Osmetech (LSE:OMH)
Historical Stock Chart
From Jan 2024 to Jan 2025